Nurse Practitioner in Greers Ferry, AR Accepting Medicare
3 Nurse Practitioner nurses found. Showing 1 - 3
 Mrs. Shannon Lee Shearer, APRN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 8544 Edgemont Rd, Greers Ferry, AR 72067 Phone: 501-825-8800 Fax: 501-825-6319 |
Kindra Daye Mckee, APRN Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 8544 Edgemont Rd, Greers Ferry, AR 72067 Phone: 501-825-8800 |
Ms. Cheryl L Golden, A.P.N. Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 8544 Edgemont Rd, Greers Ferry, AR 72067 Phone: 501-825-8800 Fax: 501-825-6319 |
News Archive
New research focuses on tobacco control and long-term health issues in post-conflict zones
In new research published today by King's College London - Institute of Cancer Policy and the Conflict & Health Research Group in the journal ecancermedicalscience, the difficulties of prioritising preventable disease and long term health issues in post conflict zones are explored.
FDA approves Mylan's ANDA for ER Tablets
Mylan today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Nisoldipine Extended-release Tablets, 8.5 mg, 17 mg, 25.5 mg and 34 mg.
Cholesterol-lowering drugs may protect women's hearts from damage caused during chemotherapy
Statins, common cholesterol-lowering medications, may protect women's hearts from damage caused during chemotherapy for early-stage breast cancer, according to new research published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.
Unigene second-quarter revenue decreases to $3.03 million
Unigene Laboratories, Inc. has reported its financial results for the quarter ended June 30, 2010.
NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.
› Verified 6 days ago